About the EU Project VALUE-Dx
VALUE-Dx is the first Innovative Medicines Initiative project initiated by 6 in vitro diagnostic companies who joined forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. Unique in its multidisciplinary consortium, it involves clinicians, microbiologists, health economists, social scientists, and industry, to help build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance.
The European Respiratory Society (ERS) was a consortium member of the VALUE-Dx project and was a member of the VALUE-Dx Work Package 6 “Education and Advocacy”.
The Society’s main role within this work package was the development of the VALUE-Dx e-learning platform, which made all educational material developed by the project widely available.
However, as active member of this work package, throughout the project ERS contributed and supported all education, advocacy and communication activities developed. Also, in addition of the e-learning platform, ERS has completed the following activities:
- Organisation of a scientific symposium at the ERS Congress yearly, to present the main progress of VALUE-Dx to the scientific community.
- Organisation of a webinar entitled “Rapid diagnostics to revolutionise our response to respiratory infections: Fighting Antimicrobial Resistance”
- Writing of a scientific statement on the role rapid diagnostic tests (RDT) for the diagnosis and management of community-acquired acute low respiratory tract infections (CA-LRTI).